Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 10/20 | 0.50 |
| ▸ | CXCR3 | P49682 | 2/20 | 0.48 |
| ▸ | TAS2R14 | Q9NYV8 | 4/20 | 0.48 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.47 |
| ▸ | CNR1 | P21554 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | NAMPT | P43490 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4741416 | 0.83 | TAS2R14 (0.62) | CNR2CXCR3TAS2R14CNR1MAPT | |
| SCHEMBL25378467 | 0.81 | HTT (0.50) | ALDH1A1TDP1L3MBTL1MEN1KMT2A | |
| SCHEMBL4924546 | 0.81 | CXCR3 (0.64) | CXCR3TAS2R14KCNA5ALDH1A1TDP1 | |
| SCHEMBL4743380 | 0.80 | TAS2R14 (0.54) | CNR2CXCR3TAS2R14MAPTALDH1A1 | |
| SCHEMBL4918682 | 0.80 | NAMPT (0.67) | TAS2R14ALDH1A1TDP1L3MBTL1NAMPT | |
| SCHEMBL14025445 | 0.78 | CXCR3 (0.56) | CNR2CXCR3TAS2R14KCNA5MAPT | |
| SCHEMBL4920990 | 0.78 | CNR2 (0.55) | CNR2CXCR3TAS2R14KCNA5CNR1 | |
| SCHEMBL4926437 | 0.78 | CNR2 (0.64) | CNR2CXCR3TAS2R14CNR1MAPT | |
| SCHEMBL14025406 | 0.77 | CNR2 (0.53) | CNR2CXCR3TAS2R14CNR1MAPT | |
| SCHEMBL14025432 | 0.76 | CXCR3 (0.60) | CNR2CXCR3KCNA5ALDH1A1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080261978-A1 | treating or preventing HIV infections, and in treating proliferative disorders such as inhibiting the metastasis of various cancers; 1-(4-((pyridin-2-ylmethylamino)methyl)benzyl)-3-phenylurea | METASTATIX, INC. | 2008-10-23 | — | — | US | disclosed |
| US-20080261978-A1 | treating or preventing HIV infections, and in treating proliferative disorders such as inhibiting the metastasis of various cancers; 1-(4-((pyridin-2-ylmethylamino)methyl)benzyl)-3-phenylurea | METASTATIX, INC. | 2008-10-23 | — | — | US | disclosed |
| US-20080261978-A1 | treating or preventing HIV infections, and in treating proliferative disorders such as inhibiting the metastasis of various cancers; 1-(4-((pyridin-2-ylmethylamino)methyl)benzyl)-3-phenylurea | METASTATIX, INC. | 2008-10-23 | — | — | US | disclosed |
| WO-2008109154-A1 | CHEMOKINE RECEPTOR MODULATORS | ALTIRIS THERAPEUTICS, INC. (US) | 2008-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080261978-A1 | treating or preventing HIV infections, and in treating proliferative disorders such as inhibiting the metastasis of various cancers; 1-(4-((pyridin-2-ylmethylamino)methyl)benzyl)-3-phenylurea | MKI67, CCNI, CDKN1A | CNR2 4124/4885CXCR3 248/4885TAS2R14 4808/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.